GW Pharmaceuticals

On November 16, Curaleaf Holdings announced that the company opened Tallahassee’s largest medical marijuana dispensary.

Cresco Labs (CRLBF) is slated to release its first-quarter earnings on May 29.

A recent Gallup poll data found that nearly 66% of Americans support making cannabis legal. However, this figure was the same as in 2018. This suggests a standstill in the rise in support of cannabis legalization. Moreover, nine states will be voting in 2020 on measures to allow cannabis for recreational or medical use. The […]

As market analysts increasingly predict an upcoming global recession, we take a look at the impact of a recession on cannabis stocks.

The FDA has issued warning letters to 15 companies involved in illegal sales of non-psychoactive CBD products. What’s the legal market’s potential?

GW Pharmaceuticals has received a “strong buy” rating from four analysts, while eight have rated it as a “buy” or some equivalent.

Texas has suffered huge economic losses. Many industry experts think that marijuana legalization could be a good option to revive the state’s economy.

Marijuana companies in the US have been struggling to get financial and banking access. Cannabis still isn’t legal at the federal level.

Green Thumb Industries (OTCMKTS:GTBIF) will likely report its results for the first quarter of fiscal 2020 on May 14 after the market closes. 

On Monday, GW Pharmaceuticals reported its first-quarter earnings. The company beat analysts’ revenue, EBITDA, and EPS expectations.

On Tuesday, GW Pharmaceuticals reported its fourth-quarter earnings. The company reported revenue of $109.1 million, which beat analysts’ expectations.

On Tuesday, GW Pharmaceuticals reported its fourth-quarter earnings after the market closed. For the quarter, the company reported revenue of $109.1 million.

On January 12, GW Pharmaceuticals announced its preliminary unaudited product sales report for the fourth quarter and 2019.

Analysts expect GW Pharmaceuticals to become profitable in 2020. They expect the company’s EBITDA to be $42.8 million in 2020.

GW Pharmaceuticals (GWPH) is a leading player in cannabinoid medicines. The company offers the first FDA-approved plant-derived cannabinoid medicine.

Aurora Cannabis’ (ACB) is receiving a lot of flak from analysts and investors. This happened after its disappointing first-quarter performance.

On November 11, the NHS (National Health Service) approved two cannabis-based medicines, Epidyolex and Sativex, for use in the United Kingdom.

GW Pharmaceuticals (GWPH) recently reported its QA3 results. Although its financials beat estimates, the company’s stock has fallen 18% since then.

Thirteen analysts are covering GW Pharmaceuticals in October. Nine covered the stock in October 2018. The consensus target price for the stock is $226.85.

GW Pharmaceuticals has announced the European Commission’s approval of EPIDYOLEX. This will mark its entry into all European countries, including the UK.

Charlotte’s Web Holdings (CWBHF) is scheduled to release its first-quarter earnings today and hold its earnings conference call tomorrow.

In the first nine months of 2018, INSYS Therapeutics’ net revenues declined ~40% YoY to reach $109.2 million from $65.7 million.

On January 10, INSYS Therapeutics stock closed at $4.49, which represents ~28% growth from its stock price of $3.50 at the close of markets on December 31.

GW Pharmaceuticals completed three phase 3 trials in Europe with Sativex (nabiximos), which all produced positive results.

In fiscal 2018, GW Pharmaceuticals (GWPH) reported net income and EPS of -$295.2 million and -$0.88, respectively.

In the fourth quarter of fiscal 2018, GW Pharmaceuticals (GWPH) generated revenues of $2.42 million compared to $2.45 million in the same period the prior year.

GW Pharmaceuticals is focused on the innovation, development, and commercialization of therapies from the company’s proprietary cannabinoid products.

According to GW’s fiscal 2018 fourth-quarter earnings conference call, it’s planning to launch Epidiolex in five major European markets in 2019.

On September 5, the US Department of Justice and the DEA issued a press release announcing the rescheduling of Epidiolex into Schedule V of the Controlled Substances Act.

Analysts expect GW Pharmaceuticals to report SG&A (selling, general, and administrative) expenses of $179.14 million in 2019.

Trulieve Cannabis Corp (TCNNF) is a licensed medical cannabis company set to release its Q3 2018 earnings on November 19 at 10:00 AM ET.

In this series, we’ll discuss analysts’ estimates, recommendations, and revenue estimates for marijuana biotechnology companies.

Wall Street analysts estimate that GWPH stock could increase ~6.7% over the next 12 months.

In this series, we’ll look at biotechnology companies focused on marijuana-based products and how they performed in the third quarter.

On June 25, GW Pharmaceuticals (GWPH) announced that it received FDA approval for Epidiolex (cannabidiol)—its oral solution.

The Investment Industry Regulatory Organization of Canada imposed a trading halt on Canopy Growth at 4:11 PM EST on February 16, 2018.